Syndax Pharma Enters Into Privately Negotiated Subscription Agreements For Issuance Of $250M Aggregate Principal Amount Of 2.25% Convertible Senior Notes Due 2031

Benzinga Newsdesk www.benzinga.com Positive 64.5%

Neg 0% Neu 0% Pos 64.5%

Comments

No comments yet. Be the first!